The 5-HT 2A receptor antagonist M100907 produces antiparkinsonian effects and decreases striatal glutamate

Frontiers in Systems Neuroscience

Volumn , Issue JUNE 2011, 2011, Pages

  Ansah, Twum A ^a   Ferguson, Marcus C ^a   Nayyar, Tultul ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Dopamine; Glutamate; M100907; Microdialysis; Motor deficits; MPTP; Parkinsonism; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLUTAMIC ACID; SEROTONIN 2A RECEPTOR; VOLINANSERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPARKINSONIAN EFFECT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; IN VIVO STUDY; MALE; MICRODIALYSIS; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSON DISEASE; SINGLE DRUG DOSE; TREATMENT RESPONSE; WALKING;

EID: 80053255279     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2011.00048     Document Type: Article

References (50)

1. Aghajaanian, G. K., and Marek, G. (1997). Serotonin induces excitator postsynaptic potentials in apical den drites of neocortical pyramidal cell. Neuropharmacology 36, 589-599.
2. Aghajanian, G. K., and Marek, G. (1999). Serotonin and hallucino gens. Neuropsychopharmacology 21 16S-23S.
3. Allbutt, H. N., and Henderson, J. M (2007). Use of the narrow beam tes in the rat, 6-hydroxydopamine mode of Parkinson's disease. J. Neurosc Methods 159, 195-202.
4. Altar, C. A., Wasley, A. M., Neale, R. F and Stone, G. A. (1986). Typical an atypical antipsychotic occupancy o D2 and S2 receptors: an autoradio graphic analysis in rat brain. Brai Res. Bull. 16, 517-525.
5. Anglade, P., Mouatt-Prigent, A., Agid Y., and Hirsch, E. (1996). Synapti plasticity in the caudate nucleus o patients with Parkinson's disease. Neurodegeneration 5, 121-128.
6. Balsara, J. J., Jadhav, J. H., and Chandorka A. G. (1979). Effect of drugs infuenc ing central serotonergic mechanism on haloperidol-induced catalepsy. Psychopharmacology (Berl.) 62 67-69.
7. Bartoszyk, G. D., Roos, C., and Ziegle H. (1996). 5-HT1A receptors are no involved in clozapine's lack of catalep togenic potential. Neuropharmacolog. 35, 1645-1646.
8. Bersani, G., Grispini, A., Marini, S., Pasini, A., Valducci, M., and Ciani, N. (1990). 5-HT2 antagonist ritanserin in neuroleptic-induced Parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin. Neuropharmacol. 13, 500-506.
9. 2A but not 5-HT2C receptor antagonism reduces yperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist.SKF 82958. Neuropharmacology 49, 350-358.
10. Bubser, M., Backstrom, J. R., Sanders-Bush, E., Roth, B. L., and Deutch, A. Y. (2001). Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum. Synapse 39, 297-304
11. Carlson, B. B., Wisniecki, A., and Salamone, J. D. (2003). Local injec- tions of the 5-hydroxytryptamine antagonist mianserin into substantia. nigra pars reticulata block tremulous jaw movements in rats: studies with,a putative model of Parkinsonian tremor. Psychopharmacology 165, 229-237.
12. Chassain, C., Bielicki, G., Durand, E., Lolignier, S., Essaf, F., Traore, A., and Durif, F. (2008). Metabolic changes detected by proton magnetic reso- nance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse. J. Neurochem. 105, 874-882.
13. DeLong, M. R. (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285.
14. Deutch, A. Y., and Cameron, D. S. (1992). Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46, 49-56.
15. Deutch, A. Y., Tam, S. Y., and Roth, R. H. (1985). Footshock and conditioned stress increase 3,4-dihydroxypheny-lacetic acid (DOPAC) in the ventral tegmental area but not substantia nigra. Brain Res. 333, 143-146.
16. Di Matteo, V., Pierucci, M., Esposito, E., Crescimanno, G., Benigno, A., and Di Giovanni, G. (2008). Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog. Brain Res. 172, 423-463.
17. Dluzen, D. E., Gao, X., Story, G. M., Anderson, L. I., Kucera, J., and Walro, J. M. (2001). Evaluation of nigrostriatal dopaminergic function in adult+/+ and +/- BDNF mutant mice. Exp. Neurol. 170, 121-128.
18. 2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology 59, 31-36.
19. Fernagut, P. O., Diguet, E., Bioulac, B., and Tison, F. (2004). MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp. Neurol. 185, 47-62.
20. Franklin, K. B. J., and Paxinos, G. (2008). The Mouse Brain in Stereotaxic Coordinates, 3rd Edn. San Diego: Academic Press.
21. Fredriksson, A., Plaznik, A., Sundstrom, E., Jonsson, G., and Archer, T. (1990). MPTP-induced hypoactivity in mice: reversal by L-dopa. Pharmacol. Toxicol. 67, 295-301.
22. Gresch, P. J., and Walker, P. D. (1999). Synergistic interaction between serotonin-2 receptor and dopamine D1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat. Brain Res. Mol. Brain Res. 70, 125-134.
23. Henderson, J., Yiannikas, C., and Graham, J. S. (1992). Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease. Clin. Exp. Neurol. 29, 277-282.
24. 2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277, 968-981.
25. Lavoie, B., and Parent, A. (1990). Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol. 299, 1-16.
26. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
27. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berl.) 131, 57-63.
28. Matsubara, S., Matsubara, R., Kusumi, I., Koyama, T., and Yamashita, I. (1993). Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265, 498-508.
29. Meltzer, H. Y., Matsubara, S., and Lee, J. C. (1989). The ratios of serotonin2 and dopamine2 affnities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 25, 390-392.
30. Meshul, C. K., Emre, N., Nakamura, C. M., Allen, C., Donohue, M. K., and Buckman, J. F. (1999). Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88, 1-16.
31. Meshul, C. K., Kamel, D., Moore, C., Kay, T. S., and Krentz, L. (2002). Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats. Exp. Neurol. 175, 257-274.
32. Mijnster, M. J., Raimundo, A. G., Koskuba, K., Klop, H., Docter, G. J., Groenewegen, H. J., and Voorn, P. (1997). Regional and cellular distribution of serotonin 5-hydroxy-tryptamine2a receptor mRNA in the nucleus accumbens, olfactory tubercle, and caudate putamen of the rat. J. Comp. Neurol. 389, 1-11.
33. Miller, C. H., Fleischhacker, W. W., Ehrmann, H., and Kane, J. M. (1990). Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol. Bull. 26, 373-376
34. Neal-Beliveau, B. S., Joyce, J. N., and Lucki, I. (1993). Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 265, 207-217.
35. Nicholson, S. L., and Brotchie, J. M. (2002). 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol. 9(Suppl. 3), 1-6.
36. Nyberg, S., Farde, L., Eriksson, L., Halldin, C., and Eriksson, B. (1993). 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl.) 110, 265-272.
37. 2A and 5-HT2C receptors. Brain Res. Mol. Brain Res. 23, 163-178.
38. Quinn, L. P., Perren, M. J., Brackenborough, K. T., Woodhams, P. L., Vidgeon-Hart, M., Chapman, H., Pangalos, M. N., Upton, N., and Virley, D. J. (2007). A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacolog ical validation with R-(-)-deprenyl. J. Neurosci. Methods 164, 43-49.
39. Raju, D. V., Ahern, T. H., Shah, D. J., Wright, T. M., Standaert, D. G., Hall, R. A., and Smith, Y. (2008). Differential synaptic plasticity of the corticostri-atal and thalamostriatal systems in an MPTP-treated monkey model of Parkinsonism. Eur. J. Neurosci. 27, 1647-1658.
40. Robinson, S., Freeman, P., Moore, C., Touchon, J. C., Krentz, L., and Meshul, C. K. (2003). Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp. Neurol. 180, 74-87.
41. 2A heteroceptors on thalam-ocortical glutamatergic neurons. J. Neurosci. 20, 8846-8852.
42. Scruggs, J. L., Schmidt, D., and Deutch, A. Y. (2003). The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neurosci. Lett. 346, 137-140.
43. Strome, E. M., Cepeda, I. L., Sossi, V., and Doudet, D. J. (2006). Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol. Imaging Biol. 8, 292-299.
44. Tillerson, J. L., Caudle, W. M., Reveron, M. E., and Miller, G. W. (2002). Detection of behavioral impairments correlated to neurochemical defcits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp. Neurol. 178, 80-90.
45. Tillerson, J. L., and Miller, G. W. (2003). Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of Parkinsonism. J. Neurosci. Methods 123, 189-200.
46. Urakawa, S., Hida, H., Masuda, T., Misumi, S., Kim, T. S., and Nishino, H. (2007). Environmental enrichment brings a beneficial effect on beam walking and enhances the migration of doublecortin-positive cells following striatal lesions in rats. Neuroscience 144, 920-933.
47. 2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol. Biochem. Behav. 90, 540-544.
48. Vanover, K. E., Weiner, D. M., Makhay, M., Veinbergs, I., Gardell, L. R., Lameh, J., Del Tredici, A. L., Piu, F., Schiffer, H. H., Ott, T. R., Burstein, E. S., Uldam, A. K., Thygesen, M. B., Schlienger, N., Andersson, C. M., Son, T. Y., Harvey, S. C., Powell, S. B., Geyer, M. A., Tolf, B. R., Brann, M. R., and Davis, R. E. (2006). Pharmacological and behavioral profle of N-(4-fuorophenylmethyl)-N-(1-methylpip eridin-4-yl)-N′-(4-(2-methylpropylo xy) phenylmethyl) car bamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 317, 910-918.
49. 2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J. Comp. Neurol. 370, 405-414.
50. Young, C. D., Bubser, M., Meltzer, H. Y., and Deutch, A. Y. (1999). Clozapine pretreatment modifes haloperidol-elicited forebrain Fos induction: a regionally-specifc double dissociation. Psychopharmacology (Berl.) 144, 255-263.